title: Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies.
abstract: In recent studies of transgenic models of Alzheimer's disease (AD), it has been reported that antibodies to aged beta amyloid peptide 1-42 (Abeta(1-42)) solutions (mixtures of Abeta monomers, oligomers and amyloid fibrils) cause conspicuous reduction of amyloid plaques and neurological improvement. In some cases, however, neurological improvement has been independent of obvious plaque reduction, and it has been suggested that immunization might neutralize soluble, non-fibrillar forms of Abeta. It is now known that Abeta toxicity resides not only in fibrils, but also in soluble protofibrils and oligomers. The current study has investigated the immune response to low doses of Abeta(1-42) oligomers and the characteristics of the antibodies they induce. Rabbits that were injected with Abeta(1-42) solutions containing only monomers and oligomers produced antibodies that preferentially bound to assembled forms of Abeta in immunoblots and in physiological solutions. The antibodies have proven useful for assays that can detect inhibitors of oligomer formation, for immunofluorescence localization of cell-attached oligomers to receptor-like puncta, and for immunoblots that show the presence of SDS-stable oligomers in Alzheimer's brain tissue. The antibodies, moreover, were found to neutralize the toxicity of soluble oligomers in cell culture. Results support the hypothesis that immunizations of transgenic mice derive therapeutic benefit from the immuno-neutralization of soluble Abeta-derived toxins. Analogous immuno-neutralization of oligomers in humans may be a key in AD vaccines.
authors.affiliation: Department of Neurobiology and Physiology, Northwestern University, Evanston, IL 60208, USA.
authors.forename: M P
authors.initials: MP
authors.lastname: Lambert
authors.forename: K L
authors.initials: KL
authors.lastname: Viola
authors.forename: B A
authors.initials: BA
authors.lastname: Chromy
authors.forename: L
authors.initials: L
authors.lastname: Chang
authors.forename: T E
authors.initials: TE
authors.lastname: Morgan
authors.forename: J
authors.initials: J
authors.lastname: Yu
authors.forename: D L
authors.initials: DL
authors.lastname: Venton
authors.forename: G A
authors.initials: GA
authors.lastname: Krafft
authors.forename: C E
authors.initials: CE
authors.lastname: Finch
authors.forename: W L
authors.initials: WL
authors.lastname: Klein
mesh_terms: D000544:Alzheimer Disease / Q000276:immunology* / Q000517:prevention & control*; D016229:Amyloid beta-Peptides / Q000276:immunology* / Q000633:toxicity; D000818:Animals; D000918:Antibody Specificity; D000939:Epitopes; D005455:Fluorescent Antibody Technique; D006624:Hippocampus / Q000166:cytology; D006801:Humans; D009474:Neurons / Q000166:cytology / Q000276:immunology; D018696:Neuroprotective Agents / Q000276:immunology; D016716:PC12 Cells; D010446:Peptide Fragments / Q000276:immunology* / Q000633:toxicity; D051381:Rats; D012995:Solubility; D014611:Vaccination
chemical_list: D016229:Amyloid beta-Peptides; D000939:Epitopes; D018696:Neuroprotective Agents; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42)